Showing 1881-1890 of 9096 results for "".
Dysregulation of Type 2 Immune Pathway
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/dysregulation-of-type-2-immune-pathway/48788/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses the role of type 2 inflammatory response in immune dysregulation in atopic dermatitis.The Importance of the Atopic Dermatitis Pipeline
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/derm-hub/37148/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, provides an overview of important research underway involving new therapeutics for the treatment of atopDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.DWTV Extra: Spotlight on Leadership
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-spotlight-on-leadership/54267/Practical Dermatology Editorial Board member Jennifer Soung, MD, discusses the LEADDerm meeting that she founded and why it is different from other conferences in dermatology.DWTV Extra: GPP Awareness Day
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-gpp-awareness-day/36704/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, discusses the importance of educating more clinicians about generalized pustular psoriasis (GPP) and observing GPP Awareness Day on August 13.Nemluvio Shows Efficacy in AD
https://practicaldermatology.com/videos/dermwire-tv/nemluvio-shows-efficacy-in-ad/36134/In this episode of DermwireTV, Nemluvio (nemolizumab) showed efficacy in atopic dermatitis in recent studies; strontium cream helps manage pruritus in hidradenitis suppurativa (HS); and Lisa Swanson and Peter Lio get viewers up to date on dupilumab’s effectiveness at halting atopic march.All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Analyzing Safety Data From Level Up
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuAnalysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/videos/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discussesFDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.